Herantis Pharma has dosed the first patients in the final cohort of its Phase 1b trial for HER-096, a first-in-class peptidomimetic with disease-modifying potential for Parkinson's disease.
Herantis Pharma has dosed the first Parkinson's disease patient in Part 2 of its Phase 1b trial for HER-096, following encouraging pharmacokinetic data from Part 1 showing the drug exceeds target concentration in cerebrospinal fluid.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.